Difluorocyclobutylacetylenes as positive allosteric modulators of mGluR5 with reduced bioactivation potential

详细信息    查看全文

• 作者：Andrew P. Degnan ; ^{andrew.degnan@bms.com} ; Darrell Maxwell ; Anand Balakrishnan ; Jeffrey M. Brown ; Amy Easton ; Michael Gulianello ; Umesh Hanumegowda ; Melissa Hill-Drzewi ; Regina Miller ; Kenneth S. Santone ; Arun Senapati ; Eric E. Shields ; Digavalli V. Sivarao ; Ryan Westphal ; Valerie J. Whiterock ; Xiaoliang Zhuo ; Joanne J. Bronson ; John E. Macor
• 关键词：mGluR5 ; PAMs ; Cognition ; Schizophrenia ; Bioactivation
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：15 December 2016
• 年：2016
• 卷：26
• 期：24
• 页码：5871-5876
• 全文大小：2219 K
• 卷排序：26

文摘

Schizophrenia is a serious illness that affects millions of patients and has been associated with N-methyl-d-aspartate receptor (NMDAR) hypofunction. It has been demonstrated that activation of metabotropic glutamate receptor 5 (mGluR5) enhances NMDA receptor function, suggesting the potential utility of mGluR5 positive allosteric modulators (PAMs) in the treatment of schizophrenia. Herein we describe the optimization of an mGluR5 PAM by replacement of a phenyl with aliphatic heterocycles and carbocycles as a strategy to reduce bioactivation in a biaryl acetylene chemotype. Replacement with a difluorocyclobutane followed by further optimization culminated in the identification of compound 32, a low fold shift PAM with reduced bioactivation potential. Compound 32 demonstrated favorable brain uptake and robust efficacy in mouse novel object recognition (NOR) at low doses.